Emtrisitabin etkileşimleri

antiretroviral sınıfından Emtrisitabin (Emtriva) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 55 belgelenmiş etkileşim var: 35 majör, 13 orta, 7 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (35)

  • AbakavirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Abakavir ve lamivudinantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • AdefovirantiviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals [See Warnings and Precautions (5. (Adefovir etiketi, Kutulu uyarı)

  • AtazanavirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • DarunavirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Darunavir ve kobisistatantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • DolutegravirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • DoravirinantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • EfavirenzantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Emtrisitabin ve tenofovirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • EntekavirantiviralMajör

    Therapy with BARACLUDE is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) [see Warnings and Precautions (5.2) ] . (Entekavir etiketi, Kutulu uyarı)

  • EtravirinantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • FosamprenavirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • HidroksiüreantimetabolitMajör

    Increased Toxicity with Concomitant Use of Antiretroviral Drugs Pancreatitis Pancreatitis (including fatal cases) have occurred in patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine. (Hidroksiüre etiketi, İlaç etkileşimleri)

  • KabotegravirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • KladribinantimetabolitMajör

    Antiviral and antiretroviral drugs: Avoid concomitant use. (Kladribin etiketi, İlaç etkileşimleri)

  • LamivudinantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Lamivudin ve zidovudinantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Consider alternative HCV or antiretroviral therapy to avoid increases in tenofovir exposures. (Ledipasvir ve sofosbuvir etiketi, İlaç etkileşimleri)

  • LenakapavirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Lopinavir ve ritonavirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • MaravirokantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • NevirapinantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • RaltegravirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • RifabutinantibiyotikMajör

    Bictegravir 75 mg once a day 300 mg once a day (fasted) Healthy subjects ND ↓ AUC 38% ↓ C min 56% ↓ C max 20% Co-administration of rifabutin with Biktarvy (bictegravir/emtricitabine/ tenofovir alafenamide) is not recommended due to an expected decrease in tenofovir alafenamide in addition to the reported reduction in bictegravir. (Rifabutin etiketi, İlaç etkileşimleri)

  • RifampisinantibiyotikMajör

    …Concentrations Administered with rifampin 600 mg daily, unless otherwise specified AUC = area under the time-concentration curve Drug or Drug Class and Prevention or Management Clinical Effect Antiretrovirals Prevention or Management: Concomitant use is contraindicated (see CONTRAINDICATIONS ) Atazanavir Decrease AUC by 72% Darunavir Rifampin dosage used concomitantly with… (Rifampisin etiketi, İlaç etkileşimleri)

  • RilpivirinantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • RitonavirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • Sarı kantaronBitkisel ürün ve takviyeMajör

    Sarı kantaron, bazı HIV ilaçlarının kan düzeylerini tedavinin başarısız olmasına yol açacak kadar düşürebilir. (NCCIH, St. John's Wort)

  • TenofovirantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

  • ZidovudinantiretroviralMajör

    Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (Emtrisitabin etiketi, Uyarılar ve önlemler)

Orta düzey etkileşimler (13)

  • Antiretrovirals: Patients who are on chronic buprenorphine treatment should have their dose monitored if NNRTIs are added to their treatment regimen. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

  • Dekslansoprazolproton pompası inhibitörüOrta

    Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with dexlansoprazole may reduce antiviral effect and promote the development of drug resistance . (Dekslansoprazol etiketi, İlaç etkileşimleri)

  • EluksadolinopioidOrta

    Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag Drugs that Cause Constipation Clinical Impact: Increased risk for constipation related adverse reactions and potential for constipation related serious adverse reactions Intervention: Avoid use with other drugs that may cause… (Eluksadolin etiketi, İlaç etkileşimleri)

  • Esomeprazolproton pompası inhibitörüOrta

    • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with esomeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ] . (Esomeprazol etiketi, İlaç etkileşimleri)

  • Lansoprazolproton pompası inhibitörüOrta

    Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with lansoprazole may reduce antiviral effect and promote the development of drug resistance. (Lansoprazol etiketi, İlaç etkileşimleri)

  • • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with esomeprazole magnesium may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ]. (Naproksen ve esomeprazol etiketi, İlaç etkileşimleri)

  • Omeprazolproton pompası inhibitörüOrta

    • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )]. (Omeprazol etiketi, İlaç etkileşimleri)

  • Omeprazol ve sodyum bikarbonatproton pompası inhibitörüOrta

    Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )] . (Omeprazol ve sodyum bikarbonat etiketi, İlaç etkileşimleri)

  • Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (Orlistat etiketi, Uyarılar ve önlemler)

  • Pantoprazolproton pompası inhibitörüOrta

    • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with pantoprazole may reduce antiviral effect and promote the development of drug resistance. (Pantoprazol etiketi, İlaç etkileşimleri)

  • Posakonazolazol antifungalOrta

    Anti-HIV Drugs that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Ritonavir and atazanavir are CYP3A4 substrates and posaconazole increased plasma concentrations of these drugs [see Clinical Pharmacology (12.3) ]. (Posakonazol etiketi, İlaç etkileşimleri)

  • Rabeprazolproton pompası inhibitörüOrta

    Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of drug resistance. (Rabeprazol etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikOrta

    Fixed-Dose Combination of Efavirenz, Emtricitabine, and Tenofovir Once-weekly coadministration of 900 mg PRIFTIN with the antiretroviral fixed-dose combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in HIV-infected patients did not result in any substantial change in steady state exposures of efavirenz, emtricitabine,… (Rifapentin etiketi, İlaç etkileşimleri)

Minör değinmeler (7)

  • BuprenorfinopioidMinör

    Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

  • Divalproeks (valproat)antikonvülsanMinör

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (Divalproeks (valproat) etiketi, Uyarılar ve önlemler)

  • FamsiklovirantiviralMinör

    The potential for drug interactions with EMTRIVA has been studied in combination with AZT, indinavir, d4T, famciclovir, and tenofovir DF (TDF). (Emtrisitabin etiketi, İlaç etkileşimleri)

  • HidrokortizonkortikosteroidMinör

    Examples: Anti-fungals: itraconazole, posaconazole, voriconazole Antibiotics: erythromycin and clarithromycin Antiretrovirals: ritonavir Grapefruit juice CYP3A4 Inducers Clinical Impact: Hydrocortisone is metabolized by cytochrome P450 3A4 (CYP3A4). (Hidrokortizon etiketi, İlaç etkileşimleri)

  • Anti-HIV efavirenz, maraviroc, nevirapine, zidovudine, bictegravir/ emtricitabine/ tenofovir ↑ efavirenz ↑ maraviroc ↑ nevirapine ↓ zidovudine ↑ bictegravir ↔ emtricitabine ↑ tenofovir For further information, refer to the respective anti-HIV drugs prescribing information. (Nirmatrelvir ve ritonavir etiketi, İlaç etkileşimleri)

  • Antiretrovirals: atazanavir lopinavir ↑ voxilaprevir Coadministration of VOSEVI with atazanavir- or lopinavir-containing regimens is not recommended. tipranavir/ritonavir ↓ sofosbuvir ↓ velpatasvir Coadministration is not recommended. (Sofosbuvir ve velpatasvir etiketi, İlaç etkileşimleri)

  • Valproik asitantikonvülsanMinör

    Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. (Valproik asit etiketi, Uyarılar ve önlemler)

Kullandığınız her şeyi Emtrisitabin ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.